Genetics
CETP promoter -1337 CC genotype doubles coronary atherosclerosis risk in Japanese familial hypercholesterolaemia patients (Clin Sci 2006)
Original title: CETP (cholesteryl ester transfer protein) promoter -1337 C>T polymorphism protects against coronary atherosclerosis in Japanese patients with heterozygous familial hypercholesterolaemia
Researchers investigated the CETP promoter -1337 C>T and hepatic lipase (LIPC) promoter -514 C>T polymorphisms in 206 Japanese patients (154 men) with heterozygous familial hypercholesterolaemia (FH), evaluating coronary atherosclerosis by coronary stenosis index (CSI) from angiograms. The CETP -1337 T allele was less frequent among patients with a CSI at or above the mean of 14 (P=0.04), though HDL cholesterol and triglyceride levels were not significantly higher with the T allele alone; combined with LIPC -514 CC genotype, HDL-C was highest and CSI lowest in CETP -1337 CT+TT carriers, though the interaction was not statistically significant. Multiple logistic regression identified the CETP -1337 CC genotype as a significant risk factor for coronary atherosclerosis in FH patients (odds ratio, 2.022; P=0.0256), independent of HDL-C and triglyceride levels. The authors conclude the CETP promoter -1337 C>T polymorphism is associated with coronary atherosclerosis progression in Japanese FH patients.
Original abstract
CETP (cholesteryl ester transfer protein) and HL (hepatic lipase) play a role in the metabolism of plasma lipoproteins, but the effects of CETP and LIPC (gene encoding HL) genotypes on coronary atherosclerosis may be dependent on LDL (low-density lipoprotein)-receptor activity. Recently, the -1337 C>T polymorphism in the CETP gene has been reported in REGRESS (Regression Growth Evaluation Statin Study) to be a major determinant of promoter activity and plasma CETP concentration. In the present study, we have investigated the effects of the CETP promoter -1337 C>T and LIPC promoter -514 C>T polymorphisms on serum lipid profiles and risk of coronary atherosclerosis in 206 patients (154 males) with heterozygous FH (familial hypercholesterolaemia). To evaluate coronary atherosclerosis, we used CSI (coronary stenosis index) calculated from coronary angiograms. The CETP -1337 T allele was less frequent in subjects with a CSI > or =14 (mean value) in the group with coronary artery disease (P=0.04, as determined by chi(2) test). ANOVA revealed that HDL-C (high-density lipoprotein-cholesterol) and triacylglycerol (triglyceride) levels were not significantly higher in the presence of the CETP promoter -1337 T allele. Combined with LIPC promoter polymorphisms, HDL-C levels were highest and CSI were lowest with CETP -1337 CT+TT and LIPC -514 CC genotypes, but a significant interaction was not shown. A multiple logistic regression analysis revealed that, in patients with coronary atherosclerosis, the CETP- 1337 CC genotype was a significant genetic risk factor in FH (odds ratio=2.022; P=0.0256). These results indicate that the CETP promoter -1337C>T polymorphism is associated with the progression of coronary atherosclerosis in Japanese patients with FH, independent of HDL-C and triacylglycerol levels.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.